Relay Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Relay Therapeutics, Inc. carries a market capitalization of 3.75B, placing it among publicly traded companies globally. Its enterprise value stands at 3.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.75B |
| Enterprise Value | 3.21B |
Share Statistics
Relay Therapeutics, Inc. currently has 218.53M shares outstanding.
| Shares Outstanding | 218.53M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 329.23, and the price-to-book ratio stands at 4.59.
| PE Ratio | N/A |
| PS Ratio | 329.23 |
| PB Ratio | 4.59 |
| P/TBV Ratio | 4.59 |
| P/FCF Ratio | -16.06 |
| P/OCF Ratio | -16.06 |
Enterprise Valuation
| EV / Sales | 309.99 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Relay Therapeutics, Inc. maintains a current ratio of 18.27, meaning it holds 18.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 18.27 |
| Quick Ratio | 17.93 |
| Debt / Equity | 3.44 |
| Debt / EBITDA | -0.10 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -36.77 |
| Return on Assets (ROA) | -33.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Relay Therapeutics, Inc.'s stock has gained approximately 139.35574% over the past 52 weeks. The 50-day moving average sits at 18.79, while the 200-day moving average is 14.52.
| Beta (5Y) | N/A |
| 52-Week Price Change | 139.35574% |
| 50-Day Moving Average | 18.79 |
| 200-Day Moving Average | 14.52 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Relay Therapeutics, Inc. generated 10.35M in revenue and converted that into -286.04M in net income, yielding earnings per share of -1.57. EBITDA reached -308.22M, while operating income came in at -310.43M.
| Revenue | 10.35M |
| Gross Profit | N/A |
| Operating Income | -310.43M |
| Pretax Income | -286.04M |
| Net Income | -286.04M |
| EBITDA | -308.22M |
| EBIT | -310.43M |
| Earnings Per Share (EPS) | -1.57 |
Balance Sheet
Relay Therapeutics, Inc. holds 910.93M in cash and equivalents against 30.66M in total debt, resulting in a net debt position of -121.19M. Total book value stands at 890.01M, with working capital of 877.28M providing operational flexibility.
| Cash & Cash Equivalents | 910.93M |
| Total Debt | 30.66M |
| Net Debt | -121.19M |
| Equity (Book Value) | 890.01M |
| Book Value Per Share | 4.07 |
| Working Capital | 877.28M |
Cash Flow
Relay Therapeutics, Inc. produced -212.20M in operating cash flow over the past twelve months.
| Operating Cash Flow | -212.20M |
| Capital Expenditures | N/A |
| Free Cash Flow | -212.20M |
| FCF Per Share | -1.17 |
Margins
Relay Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,999.37 and net profit margin of -2,763.64 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -2,999.37 |
| Pretax Margin | -2,763.64 |
| Profit Margin | -2,763.64 |
| EBITDA Margin | -2,978.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -11.34 |
| FCF Yield | -6.23 |
Scores
Relay Therapeutics, Inc. posts an Altman Z-Score of 28.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 28.57 |